Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Overviews clinical utility and patient considerations in the use of the monoclonal humanised antibody ofatumumab in chronic lymphocytic leukaemia (CLL). Looks at ofatumumab in relapsed/refractory CLL and in treatment-naïve patients, as single agent and in combination therapy, noting observational retrospective studies. Addresses the efficacy of ofatumumab retreatment and maintenance. Discusses toxicity. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.